TRAIL R2

TRAIL R2

TRAIL R2 Molekülinformation

Molecule Name
Tumor necrosis factor receptor superfamily member 10B
Molekülalias
TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB
Drug Development Progress
Anzahl der klinischen Arzneimittel10
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
Tumor necrosis factor receptor superfamily member 10B,CD262,DR5,KILLER,TRAILR2,Death receptor 5,TRAIL-R2,UNQ160/PRO186,TNFRSF10B,TNF Receptor Superfamily Member 10b,TNF-Related Apoptosis-Inducing Ligand Receptor 2,TRICK2,ZTNFR9,P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer),Tumor Necrosis Factor Receptor-Like Protein ZTNFR9,Death Domain Containing Receptor For TRAIL/Apo-2L,Apoptosis Inducing Protein TRICK2A/2B,Apoptosis Inducing Receptor TRAIL-R2,Cytotoxic TRAIL Receptor-2,Fas-Like Protein,TRAIL Receptor 2,CD262 Antigen,KILLER/DR5,TRICK2A,TRICK2B,TRICKB,Tumor Necrosis Factor Receptor Superfamily, Member 10b
Molekülhintergrund
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain. TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

TRAIL R2 Produktliste

Species
  • Human(4)
  • Cynomolgus(1)
  • Mouse(1)
Tag
  • His Tag(4)
  • Fc Tag(1)
  • His Tag & Avi Tag(1)
Host
  • HEK293(6)
Conjugate
  • Unconjugated(4)
  • Biotin-labeled(1)
  • FITC Labeled(1)
Grade
  • RUO(6)
Low Endotoxin
  • Yes(3)
  • No(3)
You Have Viewed 1-6 Of 6 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Dulanermin (Shanghai GeBaiDe)Phase 3 ClinicalShanghai Gebaide Biotechnology Co Ltd
Carcinoma, Non-Small-Cell Lung
Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech)Phase 3 ClinicalShenzhen Sinobioway Xinpeng Biomedicine Co Ltd
Neoplasms
Details
TLY-012TLY-012Phase 1 ClinicalTheraly Fibrosis
Fibrosis; Liver Cirrhosis; Pancreatitis; Pancreatitis, Chronic; Scleroderma, Systemic
Details
BI-905711BI-905711Phase 1 ClinicalBoehringer Ingelheim International Gmbh
Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms
Details
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma)CTB-006Phase 1 ClinicalBeijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd
Solid tumours
Details
OzekibartJCT-205; INBRX-109Phase 1 ClinicalInhibrx Inc
Adenocarcinoma
Details
TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim International Gmbh
Neoplasms
Details
RC-248RC-248; RC248Phase 1 Clinical
Solid tumours
Details
IBI-3004IBI-3004; IBI3004Phase 1 Clinical
Colorectal Neoplasms; Solid tumours
Details
Oba-01Oba-01; Oba01Phase 1 ClinicalYantai Heyuanaidisi Biomedical Technology Co Ltd
Carcinoma, Non-Small-Cell Lung
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
AponerminApprovedBeijing Shadong Biotech Co Ltd沙艾特, ShaiteMainland ChinaMultiple MyelomaWuhan Hiteck Biological Pharma Co Ltd2023-11-02
Multiple Myeloma
Details
Customer Reviews